Drug shortages continue to worry healthcare industry workers, especially with the launch of Obamacare on October 1, 2013. While notification has been prompt from the FDA as to which drugs are in danger of becoming in short supply, many medications which are already minimally available have not seen a respite.
The once planned generic program created by the FDA has fallen short, as there is a significant lack of manufacturers in the drug marketplace. As of mid-September 2013 active drug shortages were recorded at high levels. In fact, the close of the third quarter of 2013 showed 302 ongoing active drug shortages, which was greater than the amount at the close of the third quarter in 2012, which logged 282 shortages. The situation is not projected to get better anytime soon, and experiencing a drug shortage is becoming more commonplace.
Cancer patients have experienced a particularly difficult time during this current pharmaceutical snafu. At the beginning of the summer of 2013 a startling report regarding cancer drug shortages was revealed at the American Society of Clinical Oncology (ASCO) annual meeting. Of the cancer specialists nationwide reporting, 83 percent of these specialists reported a drug shortage in the most recent six month period of time, which negatively affected their practice. A staggering 92 percent of these physicians stated that the current drug shortage has also adversely affected their patients’ health and quality of treatment. It is obvious that the United States, as well as many countries worldwide have a dangerous situation brewing, which needs to be remedied as soon as possible.
Supplying API’s During the Drug Shortage
Clients can find current drug shortage API’s available on LGM Pharma’s website, such as:
|Product Name||CAS#||TAPI API Availability|
Research and development teams need to easily access quality API’s. LGM Pharma is the optimum source for these quality pharmaceutical products, as well as a continued support system for all clients throughout the research and development process. Clients seeking any of the API products currently experiencing a drug shortage should contact LGM Pharma immediately. LGM Pharma is a preferred supplier of over 2,500 API’s to clients worldwide.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.